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Pancreatic Neuroendocrine Neoplasms (pNEN) are rare tumors which treatment still
represent an important clinical problem, due to the paucity of medical treatments. Due to
tumor complexity, techniques as 3D cultures are important to study drug activity in a more
realistic model. This study aims to compare three different 3D culture methods in order
to understand which one can be considered the best option in terms of experimental
easiness and reproducibility in studying the efficacy of a target drug on pNEN. The
BON1 cell line was used as a pNENmodel and the well-known Receptor Tyrosine Kinase
inhibitor Sunitinib was used in order to better investigate the different features of each
method. The investigated methods are: (1) 96-well hanging drop plates (HD plates),
(2) 24-well plates with a cell-repellent surface, and (3) ultra-low attachment 96-well
plates with clear round bottom (ULA plates). The evaluated parameters during the study
were: cell seeding, easiness in spheroids formation, morphology, culture maintenance,
medium change, spheroids monitoring, picture quality, spheroid perimeter measurement
reproducibility error, possibility to perform assays into the seeding plate, overall time of the
experiment. Moreover, we investigated how culture methods can influence experimental
outcomes evaluating perimeter changes, cell viability and immunohistochemistry of
spheroids treated with different Sunitinib concentrations. Results showed that each
method has weak and strong points but, considering the easiness of spheroids
maintenance and reproducibility results, ULA plates method appears to be the best
approach to culture BON1 spheroids and, therefore, to study pNEN.
Keywords: 3D culture, pancreatic neuroendocrine neoplasms, BON1, spheroids, Sunitinib
INTRODUCTION
Pancreatic Neuroendocrine Neoplasms (pNEN) are malignancies arising from the Islets of
Langerhans and, therefore, are different from the more frequently occurring exocrine pancreas
cancer (1). pNEN represent 7% of all NEN and∼2% of all pancreatic neoplasms with an incidence
of 1–2 per 100,000 persons per year (2). pNEN diagnosis is mostly influenced by hormonal
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hypersecretion that usually leads to early diagnosis due to the
manifestation of clinical symptoms (3). However, since up to
85% of patients do not display a specific syndrome, pNEN
are often discovered incidentally at advanced stages or due
to the presence of local compressive symptoms (2). Surgical
resection remains the most effective treatment, but >50% of
NEN are not resectable at diagnosis (4, 5). Therefore, alternative
approaches are employed, such as biotherapy, targeted therapies,
chemotherapy, radiotherapy, Peptide Receptor Radionuclide
Therapy (5). It is well-known that Somatostatin Analogs are
effective in controlling symptoms and in stabilizing tumor
growth in specific settings and the beneficial effects of the
approaches available up to now are limited (6, 7). Therefore, other
therapeutic options have been actively searched for (5, 8). Indeed,
molecular pathways involved in pNEN development and growth
have been deeply investigated during the last years, leading to
the development of molecular targeted therapies (8). Clinical
trials have already demonstrated the efficacy of Sunitinib and
Everolimus in pNEN treatment (9, 10). However, side effects or
drug resistance may limit the beneficial actions of these drugs
(9, 11). In particular, Sunitinib inhibits several receptor tyrosine
kinases (RTKs) such as Vascular Endotherlial Growth Factor
Receptor (VEGFR), Platelet-Derived Growth Factor Receptor
and KIT (12). This drug is frequently employed in the treatment
of pNEN, since this tumor type is strictly dependent on VEGFR
activation (12, 13). Understanding Sunitinib effects on pNEN has
been importantly investigated in the last years also by means
of in vitro studies, that have been essential in clarifying drug
mechanism of action (14). In particular, 3D cell cultures have
been employed in the attempt to fill the gap between in vitro and
in vivo systems, due to the possibility of partially recapitulating
tumor structure and microenvironment (15). Benefits of 3D
cultures are multiple and the most important issue is that this
approach provides a more accurate representation of a solid
tumor mass (16). As confirmed by Maltman et al. (17), 3D cell
aggregation leads to the generation of different proliferation areas
and, therefore, to different gene expression patterns and cellular
behavior in the spheroid that cannot be replicated in 2D systems.
Enhanced cell interaction and crosstalk are additional very
important characteristics of 3D cultures that contribute to the
generation of a complex microenvironment, that, again, cannot
be reproduced in 2D cultures. All these features together may
be useful for specific research aspects, that cannot be provided
by 2D systems, representing an essential asset for drug discovery
research (16, 18). Many 3D culture techniques are available and
have been optimized during the last 40 years in order to bridge
the gap between monolayers and expansive models (19). Those
methods involve different strategies for cell aggregation and,
therefore, different tools and methodologies (19). 3D culture
methods can be mainly divided into two groups according to the
presence/absence of a scaffold. In addition, differences between
methods are mostly related to the purpose of the study (20).
However, it is unclear which growth culture method is more
reliable in the study of drug effects on pNEN. In this study we
have analyzed three different “scaffold free” 3D culture methods
in order to understand which one could represent the best
option in terms of experimental easiness and reproducibility. In
order to pursue this aim, we have tested Sunitinib at different
concentrations on 3D spheroids from a pNEN cell line, the BON1
cells, obtained with different methods. We choose to employ
Sunitinib since this drug has already demonstrated a significant
inhibitory effect on BON1 cell viability in monolayer (21, 22). We
then evaluated the results of each 3D method according to their
different specific features and tried to identify which method is
the best to study drug activity in BON1 cells.
MATERIALS AND METHODS
Drugs and Chemicals
Sunitinib was purchased from Selleckchem (TX, USA),
dissolved in dimethyl sulfoxide (DMSO) and stored at −80◦C as
10mM stock solution until use.
Human Cell Line
BON1 cells, derived from human pNEN, were a kind gift from
Dr. C. Auernhammer, Medizinische Klinik II, University of
Munich, Germany. Cells were grown in 1:1 mixture of F12K
and DMEM medium (Euroclone, MI, Italy) supplemented with
10% fetal bovine serum (FBS), 10 µ/ml Penicillin/Streptomycin,
referred to as “complete medium” at 37◦C in a humidified
atmosphere with 5% CO2. Experiments were performed within
the 7th passage (23).
3D Model
3D spheroids were obtained using three different methods.
The first method employs 96-well hanging drop plates
(Perfecta 3D, 3D Biomatrix, MI, USA). Cells were seeded at 2.4
× 103 cells/well in 30 µl/well complete medium and allowed
to form compact 3D aggregates. Two days after seeding and
spheroids formation, aggregates weremoved into another 96-well
plate and treated with Sunitinib 2.5, 5, and 7µM. Pictures were
taken before adding treatments and before adding MTT solution
for assessing cell viability.
In the second method, 500 cells were seeded in a 24-
well plate with a repellent surface (CELLSTAR R© Cell-Repellent
Surface, greiner bio-one, KR, AU) and left on a microplate mixer
overnight at 80 rpm. The 4th day after seeding, medium was
removed and cells were treated with Sunitinib 1, 2.5, and 5µM.
Treatments were renewed after 3 days in new fresh complete
medium. Pictures were taken before adding treatments and then
at day 7 and 10 after treatment.
The third method was performed as previously described
(24, 25). Briefly, 30 µl complete medium containing 2.4
× 103 cells were seeded in each well in an ultra low
attachment 96-well plate (Corning R© 96-well Clear Round
Bottom Ultra-Low Attachment Microplate, NY, USA). Plates
were centrifuged at 300 × g for 3min and treated with the
indicated compounds 72 h later. Treatments were performed
adding 70 µl of fresh complete medium with Sunitinib at
2.5, 5, and 7µM into each well. Pictures were taken before
adding treatments and before adding MTT solution for assessing
cell viability.
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Spheroid Size Evaluation
Spheroid size was evaluated by measuring spheroid perimeter
using Image J software (NIH, Bethesda, Maryland, USA). Results
are expressed as mean pixel measure ± S.E.M. vs. vehicle-
treated control cells from three independent experiments in two
replicates. Pictures for spheroid size evaluation were taken with
a Zeiss Axiovert 200/M-based phase-contrast microscope for the
second method. EVOS FL Cell imaging System was employed for
the first and third method.
Evaluation of Cell Viability
Variations in cell viability were detected using MTT assay
(Sigma Aldrich, St. Louis, USA). MTT assay detects NAD(P)H-
dependent cellular oxidoreductase activity, which, according
to international literature, mirrors cell viability. This enzyme
reduces the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltenyltetrazolium bromide to its insoluble formazan.
A solubilisation solution (in our case dimethyl sulfoxide) is
added to dissolve the insoluble formazan product into a colored
solution. The absorbance of the solution is then quantified with
a spectrophotometer.
BON1 cells were seeded as spheroids in a 96-well plate
as described above and treated 3 days after seeding with the
indicated compounds. Control cells were treated with vehicle
solution alone (DMSO). Spheroids were incubated with the
indicated compounds for 3 days and then 10 µl of 5 mg/ml
MTT solution were added to each well. After 1 day, 100 µl of
MTT solvent were added to each well and plates were incubated
for 4 h in order to solubilize formazan crystals. Absorbance at
570 nm was then measured with GloMax R© Explorer Multimode
Microplate Reader (Promega Corporation, WI, USA). Results
are expressed as mean value ± S.E.M. percent optical density
(OD) vs. vehicle-treated control cells from three independent
experiments in six replicates.
Immunohistochemistry
Immunohistochemistry (IHC) was performed as described by
Wong et al. (26). Briefly, spheroids were cultured and fixed
with 10% formalin, washed in 70% ethanol and embedded in
HistoGel (Thermo Scientific, HG-4000-012). After fixation
and HistoGel embedding, spheroids were embedded in
paraffin and cut in 3µm layer slides. Subsequently, sections
were deparaffinized, dehydrated, and incubated with 1:1,000
caspase 3 primary antibody (Cell Signaling, Danvers, USA)
overnight at 4◦C. All slides were counterstained with eosin
and coverslipped.
Statistical Analysis
Statistical analyses were carried out using ANOVA after proof
of homogeneity of variances and normality tests. Data were
analyzed using GraphPad (Prism v-7.0); P < 0.05 were
considered significant (∗). For all the other experiments, if not
otherwise indicated, Student’s paired or unpaired t-test was
used to evaluate individual differences between the means, and
P < 0.05 were considered significant.
Experimental reproducibility was evaluated by assessing
reproducibility error, represented as the mean difference
between the maximum and minimum measurement for each
assessed variable.
RESULTS
Influence of Sunitinib on BON1 Spheroids
Cultured Using a 96-Well Hanging Drop
Plate
BON1 cells were cultured using a 96-well hanging drop plate
and treated with Sunitinib at different concentrations chosen
on the basis of previous experiments (21). Spheroids pictures
were taken before adding Sunitinib (3 days after seeding)
and before adding MTT (7 days after seeding). As shown
in Figure 1A, pictures taken at day 3, while spheroids were
inside the hanging drop plate, are blurred and unclear. This
peculiarity is due to the conformation of the plate and to the
fact that spheroids are in suspension inside a drop; all these
features hamper the possibility to take clear and focused pictures.
After spheroids transfer into a 96-well plate with ultra-low
attachment bottom (7 days after seeding) pictures appear clearer
and more defined. This procedure implies several passages that
amplify the likelihood of mistakes, prolongs hands-on time and
increase experimental variability (Table 1). Analysis of spheroids
perimeter was performed both 3 and 7 days after seeding and
is presented in Figure 1B. This evaluation showed that there
is no significant difference between mean perimeter of vehicle
treated spheroids and mean perimeter of spheroids treated with
different Sunitinib concentrations. These results are due to the
great variability of the performed measurements, as indicated by
a very high reproducibility error (see Table 1). Therefore, this
method does not appear to be highly reproducible.
At day 7 MTT analysis was performed in order to assess
Sunitinib effects on cell viability. As shown in Figure 1C,
treatment with Sunitinib significantly reduced cell viability
by ∼20% at all concentrations tested (P < 0.05 vs. vehicle-
treated cells).
Influence of Sunitinib on BON1 Spheroids
Cultured Using 24-Well Plates With a
Repellent Surface
In order to compare the differences between 3D culture
methods, we generated BON1 spheroids with a different
method employing a 24-well plate with a repellent surface.
Spheroids were seeded and then treated with different Sunitinib
concentrations at day 4 and at day 7 after seeding. Pictures
were taken before each treatment and before fixation for
IHC studies.
In order to understand Sunitinib action on this type of 3D
BON1 culture we evaluated changes in spheroids perimeter. As
shown in Figure 2A, at day 4 spheroids perimeter was highly
homogeneous. No detectable changes in spheroids size were
observed at day 7 (Figure 2B, left panel), while at day 10
after treatment with Sunitinib 1 and 2.5µM spheroid perimeter
decreased by ∼13 and 15%, respectively (P < 0.01 vs. vehicle-
treated cells) (Figure 2B, right panel). At day 10 spheroids treated
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FIGURE 1 | Hanging drop method. BON1 cells were seeded into a 96 well hanging drop plate and treatments with Sunitinib were performed after spheroids transfer
in a regular 96 well plate. (A) In the upper lane (Day 3) pictures were taken at day 3 after seeding inside the 96 hanging drop plate with EVOS FL Cell imaging System
(10 × objective); in the lower lane (Day 7) spheroids pictures were taken at day 7 after transfer in a regular 96 well plate. Spheroids were treated at day 3, after transfer
from the first to the second plate, with Sunitinib 2.5, 5, and 7µM. (B) Perimeter analysis of spheroids was performed at day 3 and 7 and represented in a graph. Gray
column: perimeter analysis at Day 3, before treatments. White columns: perimeter analysis at Day 7 under indicated treatments. The analysis was performed using
Image J software and measurements were performed from three independent experiments in two replicates. (C) Cell viability was measured as absorbance in three
independent experiments with six replicates each, and it is expressed as the mean ± S.E.M. *P < 0.05 vs. vehicle cells.
with Sunitinib 5µM displayed an extremely irregular and loose
shape, therefore perimeter analysis could not be performed.
In order to explore further possibilities offered by this
culture method, we evaluated Caspase 3 activation by means
IHC analysis. As shown in Figure 2C, Caspase 3 IHC can
be performed on spheroids treated with Sunitinib 1 and
2.5µM. IHC of spheroids treated with Sunitinib 5µM was not
performed due to the complete spheroid disaggregation during
the procedure.
This method needs medium refreshment (not only
supplementation), which means that the medium
has to be replaced at least twice before fixation,
running the risk of inadvertently discarding spheroids.
Reproducibility error could not be calculated due to
the loss of a high number of spheroids during the
procedure (Table 1).
Influence of Sunitinib on BON1 Spheroids
Cultured Using an Ultra Low Attachment
96-Well Plate
BON1 cells were also cultured with a third method involving a
96-well plate with an ultra low attachment bottom (ULA) in order
to further investigate the differences between available 3D culture
methods. As shown in Figure 3A, spheroids were treated with
different Sunitinib concentrations and pictures were taken 3 and
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TABLE 1 | Comparison of the results obtained for 3D spheroids with the three
different methods.
3D culture methods
96-well
hanging
drop plate
24-well plate with
a cell-repellent
surface
Ultra-low
attachment
96-well plates
Cell seeding Easy Easy Easy
Easiness in
spheroids formation
Easy Intermediate Easy
Morphology Round type
with jagged
edges
Round-type Round-type
Culture
maintenance
Difficult Difficult Easy
Medium change Difficult Difficult Difficult
Spheroids
monitoring
Difficult Intermediate Easy
Picture quality Low High High
Spheroid perimeter
measurement
reproducibility error
2.9 × 106
pixels
N. A. 1.2 × 106
pixels
Possibility to
perform assays into
the seeding plate
No No Yes
Overall time of the
experiment
7 days 10 days 7 days
Reproducibility error is not available for spheroids seeded with the second method since
several spheroids were thrown away during medium refreshing.
7 days after seeding. The plate conformation improves the quality
of the pictures, that appear clear and focused.
Spheroids perimeter was then investigated; we found a
significant decrease in this parameter at day 7 after treatment
with Sunitinib 2.5µM by ∼18% (P < 0.05 vs. vehicle-treated
cells) and treatment with Sunitinib 5 and 7µM by ∼21%
(P < 0.05 vs. vehicle-treated cells) (Figure 3B).
Moreover, as shown in Figure 3C, MTT assay showed that
Sunitinib at 2.5, 5, and 7µM significantly decreases cell viability
by∼20% (P < 0.01 vs. vehicle-treated cells).
This method does not need spheroid transfer nor medium
refreshment, since medium can be supplemented directly
in culture wells. Therefore, there is no risk of discarding
spheroids. In addition, less replicates are sufficient and
reduced incubation times are needed as compared to the
previous method in order to observe Sunitinib effects on
BON1 spheroids. Variability of the performed measurements
is reduced, as indicated by a reproducibility error that is less
than half as compared to that recorded for the first method
(see Table 1).
DISCUSSION
In the current study for the first time, to the best of our
knowledge, three 3D culture methods using a pNEN cell line
were compared. We found, as expected, that each method
present weak and strong points, as well as different experimental
outcomes. Our results indicate that the best option in terms of
experimental easiness and reproducibility to test Sunitinib effects
on BON1 3D spheroids is represented by the method employing
ULA plates (Figure 4).
3D cultures represent an easy and effective way to
reproduce a solid mass and mimic tissue key interactions,
obtaining more realistic and trustworthy results. Since
several methods are available to generate this type of
culture, our purpose was to compare different 3D scaffold-
free culture systems in order to understand which one
could be the best option in the study of pNEN in terms
of easiness of culture method and results reproducibility.
Therefore, we cultured BON1 cells using three different
culture systems.
In the first method, BON1 cells were cultured using a 96-
well hanging drop plate. This method is indicated to perform
drug screening/cytotoxicity assays and, as underlined by several
research groups, its most interesting feature is represented
by the exploitation of cell natural tendency to aggregate
without scaffolds/matrix involvement (17, 27). The hanging drop
method offers several advantages, mainly represented by the
easiness of protocol procedures for spheroid formation. On
the other hand, according to our experience with the BON1
cell line, spheroids transfer after day 3 was problematic and
led to spheroids disaggregation. This observation has been
documented also by Amaral et al., who confirm that one of
the major weak points of the method is the need to transfer
the spheroids to a conventional 96-well plate in order to
carry out cytotoxicity assays (28). Structural alterations during
spheroids transfer have also been reported by other research
groups with different cell lines (29), indicating that this issue
appears to be related to the culture method rather then to
the cell type. Another disadvantage of this method is the
impossibility to refresh spheroids medium due to the small
seeding volume (30 µl). Indeed, medium cannot be replaced,
since this procedure would imply the presence of a microscope
under the cell culture hood to ensure that spheroids are not
lost during medium replacement. Therefore, spheroids must be
transferred to another plate in order to allow medium/treatment
addition. This peculiarity has been documented by several
research groups and can represent an important weak point
(17, 27, 30). Moreover, it is difficult to find the correct focus
while spheroids are located in the hanging drop plate; this feature
limits the possibility to take good quality pictures, hampering
spheroids perimeter measurements. Indeed, we found a higher
reproducibility error for the first 3D method as compared
to the third 3D method in terms of perimeter measurement.
Since one of the main possibilities offered by this culture
method is to perform drug screening and cytotoxic assays
we performed MTT assay on BON1 spheroids treated with
Sunitinib. Observed cell viability reduction was significant for
all the concentrations tested with small variability, indicating
MTT analysis as a good method for assessing drug effects on
spheroids viability.
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FIGURE 2 | 24-well plate with a cell-repellent surface method. BON1 cells were seeded into a 24 well plate with a repellent surface, mixed overnight at 80 rpm.
(A) Spheroids were treated with increasing Sunitinib concentrations and pictures were taken at day 4, 7, and 10 after seeding with a Zeiss Axiovert 200/M-based
phase-contrast microscope (5 × objective). (B) Perimeter analysis of spheroids was performed at day 4, 7, and 10. Gray column: perimeter analysis at Day 4, before
treatments. White columns: perimeter analysis at Day 7 and 10 under indicated treatments. The analysis was performed using Image J software and measurements
were performed evaluating three independent experiments in two replicates. **P < 0.01 vs. vehicle cells at Day 10. § = 5µM measurement was not detectable for
technical reasons, as indicated in the results section. (C) Immunohistochemical expression of Caspase 3 in spheroids treated with different Sunitinib concentrations.
Spheroids were fixed at day 10 and pictures were taken with a Zeiss Axiovert 200/M-based phase-contrast microscope. Pictures provide an overview of the entire
spheroid stained with eosin and Caspase 3 antibody.
The second method involves a 24-well plate with a cell
repellent surface. The most important characteristic concerns
spheroids size that, being bigger, allows to perform several
assays, including IHC. Cell seeding is very easy and involves
only plates with a low attachment bottom and a shaker.
This method allows to form spheroids with a regular round
shape and, due to the flat bottom well, to take good quality
pictures. Heterogeneous spheroids proliferation rate, oxygen and
nutrients gradients and good cell-cell contacts are important
features of scaffold free systems involving the use of a shaker,
as also underlined by other research groups (31). However,
medium refreshing represents one of the most tricky and
challenging aspects of this culture method: spheroids are
difficult to locate in the well and, therefore, could be easily
discarded during the procedure. Therefore, many replicates are
needed to reduce variability of the performed measurements
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FIGURE 3 | ULA plate method. BON1 cells were seeded into an ultra low attachment 96 well plate and spheroids were obtained by centrifugation. (A) Spheroids
were treated with increasing Sunitinib concentrations and pictures were taken with EVOS FL Cell imaging System (10 × objective) at Day 3 and 7 after seeding.
(B) Perimeter analysis of spheroids was performed at Day 3 and 7. Gray column: perimeter analysis at Day 3, before treatments. White columns: perimeter analysis at
Day 7 under indicated treatments. The analysis was performed using Image J software and measurements were performed from three independent experiments in
two replicates. *P < 0.05 vs. vehicle cells. (C) Cell metabolic activity was measured as absorbance in three independent experiments with six replicates each, and it is
expressed as the mean ± S.E.M. **P < 0.01 vs. vehicle cells.
and allow reproducibility. Similarly to the previous method,
spheroids were treated with different Sunitinib concentrations
in order to measure perimeter variations. This method allows
to detect significant differences in perimeter measurements
10 days after seeding, but may not be ideal to assess the
efficacy of cytotoxic drugs at high concentrations. Indeed, in
these condition spheroids integrity was compromised in our
hands, preventing spheroid perimeter evaluation. In addition,
Herrera Martìnez et al. recently demonstrated that in BON1
spheroid obtained by using the 24-well plate with cell repellent
surface spheroids size does not correlate with DNA content
(32). Therefore, spheroids perimeter analysis is not reliable as
a measurement of drug cytotoxicity for 3D spheroid cultured
with this method. In addition, MTT evaluation is hardly feasible
since spheroids should be transferred to a different smaller
plate. However, the most interesting feature of this method
is the possibility to perform IHC analysis, that allows to
explore protein expression/activation directly in the different
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FIGURE 4 | Summary figure. Illustration of the steps of the different methods evaluated in the study.
spheroid areas, helping to better understand drug mechanisms
of action.
The third and last scaffold-free method involves an ULA
96-well plate. In this setting, spheroids formation is enhanced
by centrifugation that promotes cells proximity. From the very
beginning BON1 spheroids appear very compact and with
round type morphology; these characteristic have been indicated
to be strongly related to a robust cell-cell adhesion, a key
feature for 3D models (28, 33). The well shape promotes
the formation of a single spheroid for each well, centrally
located; moreover, pictures can be easily taken. Similarly to the
hanging drop method, spheroids generated with ULA plates
are suitable for drug testing with the difference that there is
no need to transfer 3D cultures from one plate to another to
perform cytotoxicity assays. Spheroids are seeded inside the
plate in a 30 µl volume and treatment can be performed
directly adding medium into the wells, without transferring
the spheroids. This is one of the most interesting features of
this method, since the spheroids are treated in the seeding
well and, therefore, are not stressed by transfer, avoiding
the risk to damage the 3D structure. Spheroids perimeter
was evaluated as for the previous methods and its analysis
showed significant results. Indeed, a smaller reproducibility
error for perimeter measurement in spheroids seeded with
ULA plates was found as compared to the hanging drop
method, indicating a better reproducibility. Moreover, ULA
plates method allows MTT analysis, that appears to show a
higher sensitivity in detecting viability variations as compare
to the hanging drop method, probably due to the spheroids
higher homogeneity.
In conclusion, we found that ULA plates method allows to
obtain the most reproducible results when assessing perimeter
evaluation in BON1 spheroids as compared to the other
investigated methods. In addition, the possibility to generate
a single spheroid in each well, that is not disturbed nor
altered due to plate transfer/medium refreshment, allows
to obtain better results also in following studies, such as
viability/cytotoxicity assays.
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